Land: Kanada
Sprache: Englisch
Quelle: Health Canada
CEFAZOLIN (CEFAZOLIN SODIUM)
FRESENIUS KABI CANADA LTD
J01DB04
CEFAZOLIN
500MG
POWDER FOR SOLUTION
CEFAZOLIN (CEFAZOLIN SODIUM) 500MG
INTRAMUSCULAR
10ML
Prescription
FIRST GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0109442002; AHFS:
APPROVED
2006-10-05
_CEFAZOLIN FOR INJECTION, USP (Cefazolin for Injection) _ _Page 1 of 26 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CEFAZOLIN FOR INJECTION, USP Cefazolin for Injection Powder for Solution, 500 mg and 1 g cefazolin (as cefazolin sodium) per Vial Powder for Solution, 10 g and 20 g cefazolin (as cefazolin sodium) per Pharmacy Bulk Vial Powder for Solution, 100 g cefazolin (as cefazolin sodium) per SmartPak ® Pharmacy Bulk Package Intramuscular, Intravenous Antibiotic Fresenius Kabi Canada Ltd. 165 Galaxy Blvd, Suite 100 Toronto, ON M9W 0C8 Date of Initial Authorization: JAN 28, 1998 Date of Revision: SEP 13, 2022 Submission Control Number: 263265 _CEFAZOLIN FOR INJECTION, USP (Cefazolin for Injection) _ _Page 2 of 26 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Skin 09/2022 7 WARNINGS AND PRECAUTIONS, Renal 09/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 5 1.2 Geriatrics ................................................................................................................... 5 2 CONTRAINDICATIONS ................................................................................................. 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ................................................ Lesen Sie das vollständige Dokument